Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Non Operating Income (2018 - 2025)

Adma Biologics (ADMA) has disclosed Other Non Operating Income for 8 consecutive years, with -$17000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 100.38% year-over-year to -$17000.0, compared with a TTM value of -$212000.0 through Dec 2025, down 104.94%, and an annual FY2025 reading of -$212000.0, down 104.88% over the prior year.
  • Other Non Operating Income was -$17000.0 for Q4 2025 at Adma Biologics, down from $1.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $7.5 million in Q4 2022 and bottomed at -$26.0 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$1.2 million, with a median of -$31000.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income surged 4128.0% in 2022, then crashed 7000.0% in 2025.
  • Year by year, Other Non Operating Income stood at -$187229.0 in 2021, then soared by 4128.0% to $7.5 million in 2022, then tumbled by 444.6% to -$26.0 million in 2023, then surged by 117.11% to $4.4 million in 2024, then plummeted by 100.38% to -$17000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ADMA at -$17000.0 in Q4 2025, $1.0 million in Q3 2025, and -$1.1 million in Q2 2025.